Unknown

Dataset Information

0

Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?


ABSTRACT: AIM:This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment program of the University of Rome Tor Vergata. MATERIALS AND METHODS:A total of 27 nonadherent patients (21 men, six women; mean age: 36.1 years; range: 23-63 years) were enrolled. Maximum observational period was 30 months. RESULTS:A total of 12 patients were under treatment for 30 months (44.44%) but only nine had a valid 30-month follow up, while the remaining three patients initially treated at our unit continued long-acting risperidone at their local centre. Reductions of monthly mean values of Scale for the Assessment of Positive Symptoms (SAPS) [repeated measures analysis of variance (rm-ANOVA): p < 0.0001] and Scale for Assessment of Negative Symptoms (SANS) (p < 0.0001), increase of monthly mean values of Subjective Well-Being Under Neuroleptic Treatment Scale (SWN) (p < 0.0001) and Schizophrenia Quality of Life Scale (S-QoL) (p < 0.01) were observed. Significant differences with respect to SAPS baseline values from the sixth month, SANS baseline values from the seventh month, SWN baseline values from the eighth month, S-QoL baseline values from the eighteenth month were shown in post hoc tests. Reduction of SAPS mean values was associated with increase of SWN (p < 0.0001) and S-QoL (p < 0.0001) mean values as demonstrated by correlation analysis. The same inverse correlation was found between reduction of SANS mean values and increases of SWN (p < 0.0001) and S-QoL (p = 0.0001) mean values. CONCLUSIONS:Long-term treatment with long-acting risperidone may be associated with improvement to adherence to therapy and quality of life. Patients may show improvement in psychopathological symptoms, subjective well-being and quality of life.

SUBMITTER: Niolu C 

PROVIDER: S-EPMC4622121 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Niolu Cinzia C   Bianciardi Emanuela E   Di Lorenzo Giorgio G   Marchetta Claudia C   Barone Ylenia Y   Sterbini Nicoletta N   Ribolsi Michele M   Reggiardo Giorgio G   Siracusano Alberto A  

Therapeutic advances in psychopharmacology 20151001 5


<h4>Aim</h4>This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment program of the University of Rome Tor Vergata.<h4>Materials and methods</h4>A total of 27 nonadherent patients (21 men, six women; mean age: 36.1 years; range: 23-63 years) were enrolled. Maximum observational period was  ...[more]

Similar Datasets

| S-EPMC8259292 | biostudies-literature
| S-EPMC5513414 | biostudies-literature
| S-EPMC9530432 | biostudies-literature
| S-EPMC3289759 | biostudies-literature
| S-EPMC7765516 | biostudies-literature
| S-EPMC5927002 | biostudies-literature
| S-EPMC9232132 | biostudies-literature
| S-EPMC5510036 | biostudies-literature
| S-EPMC3683731 | biostudies-literature
| S-EPMC3743871 | biostudies-literature